Autism is a group of disorders characterized by abnormalities in communication and social interactions. Two common consistent findings are associated in children with this disorder are diminished oxygenation in specific areas of the brain and a chronic immunologically mediated inflammatory condition in the gut.
Current therapies for autism attempt to reverse these abnormalities through administration of antibiotics, anti‐inflammatory agents, and hyperbaric oxygen. Unfortunately, none of these approaches address the root causes of oxygen deprivation and intestinal inflammation.
The rationale behind treating autism with allogenic umbilical cord tissue-derived mesenchymal stem cells is that autism, and its degree of severity, has been significantly correlated inflammation neural tissues. Intravenous administration of umbilical cord MSCs has been shown in multiple clinical trials to decrease inflammation. Decreasing inflammation in the autistic patient may alleviate symptoms of autism.
Through administration of mesenchymal stem cells, we have seen improvement in autistic children.
The stem cells used to treat autism come from human umbilical cord tissue (allogeneic mesenchymal stem cells), donated by mothers after normal, healthy births. Before they are approved for treatment all umbilical cord-derived stem cells are screened for viruses and bacteria to International Blood Bank Standards. In some cases, we also utilize stem cells harvested from the patient’s own bone marrow.
Umbilical cord-derived stem cells are ideal for the treatment of autism because they allow us to administer uniform doses and they do not require any stem cell collection from the patient, because they are collected right after birth. Umbilical cord-derived cells are much more potent than their “older” counterparts like bone marrow-derived cells or adipose derived mesenchymal srtem cells. Cord tissue-derived mesenchymal stem cells pose no rejection risk because the body does not recognize them as foreign (They have a very weak immunogenecity. The body’s immune system is unable to recognize umbilical cord-derived mesenchymal stem cells as foreign and therefore they are not rejected. There has never been a single instance ofrejection (graft vs. host disease).
Umbilical cord-derived mesenchymal stem cells also proliferate/differentiate more efficiently than “older” cells, such as those found in the fat and therefore, they are considered to be more “potent”.
Advantages of treating with allogeneic umbilical cord tissue-derived stem cells
- Since umbilical cord tissue mesenchymal stem cells have very low immunogenecity, there is no cell rejection and Human Leukocyte Antigen (HLA) matching is not required.
- The stem cells with the best anti-inflammatory activity, immune modulating capacity, and ability to stimulate regeneration can be screened and selected.
- Allogeneic stem cells can be administered multiple times over the course of days in uniform dosages that contain high cell counts.
- Umbilical cord tissue provides an abundant supply of mesenchymal stem cells.
- No need to collect stem cells from the patient’s bone marrow or fat under anesthesia, which especially for small children and their parents, can be difficult.
- There is a growing body of evidence showing that umbilical cord-derived mesenchymal stem cells are more robust than mesenchymal stem cells from other sources.
Stem cells administration for autism treatment
The umbilical cord-derived stem cells are administered intravenously by a licensed physician.
Stem Cell Treatment: Autism Protocols
- Treatment length (Monday – Friday): 5 Days
- Physical examination and blood testing: Monday
- Daily intravenous infusions of human umbilical cord tissue-derived allogeneic mesenchymal stem cells: (Tuesday – Friday): 4 days
- The whole process is carried out our clinic.
Proper follow-up is an essential part of the autism treatment process. Our primary goal is to ensure that your child is progressing safely. Regular follow-up also enables us to evaluate efficacy and improve our autism treatment protocols based on observed outcomes.
Therefore, our medical staff will be contacting you after 1 month, 3 months, 4 months, and 1 year to monitor your child’s progress.